

Humber Area Prescribing Committee

Date / Time	7 th February 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send items to NP outside the meeting
Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Simon Priestley- Chief Pharmacist, NLAG (SP) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK) Daniel Newsome- Principal Pharmacist RDTTC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Joanne Goode – Chief Pharmacist – HUTH (JG) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Dr Pratik Basu- GP- The Birches medical practice (PB) Dr Rolan Schreiber, Medical Secretary LMC (RSc) Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)
Apologies	Luke Storr – Senior Pharmacy Technician, HUTH (LS) Narayana Pothina- Consultant in adult medicine, NLAG (NP) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS)

		<p>June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group September 2023 update: For September guideline group October 2023 update: For November Guideline group November 2023 update: For November Guideline group December 2023 update: For January or March guideline group – to check against York mycophenolate. February 2024 – reviewed against York SCF and contacted neuromuscular lead with national SCF. For March guideline group</p> <p>Outstanding actions from HERPC Renal repatriation: November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time. December update – Not met with renal yet. March update – Updating business case. May update – to meet with NHSE August update – not yet met with NHSE September update: not yet met with NHSE October update: not yet met with NHSE November update: not yet met with NHSE December update: meeting arranged with NHSE February 2024 update: meeting arranged and business case in progress</p> <p>Blueteq Non-compliance to NICE guidance in acute trusts and financial impact June update: JM to submit ustekinumab report in gastroenterology HUTH when approved JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved July update: JM to update next time. August update: no further update, infliximab audit in HUTH started</p>	Ongoing	JM	4/24
			Ongoing	JM	4/24

		<p>September update: HUTH audits still ongoing October update: HUTH audits still ongoing November update: HUTH audits still ongoing December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch. February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance.</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper. September update: September D&TC next week, further updates to pathway needed October update: Awaiting updated pathway November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch. December update: ongoing February 2024 update: JG to follow up with Dr Ogumbambi</p> <p>Ratification of guidelines and SCFs: Sick Day Guidance in T2DM JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team December 2023 – ongoing February 2024 update: ongoing</p> <p>Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites.</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM</p> <p>JM</p> <p>JM</p>	<p>4/24</p> <p>2/24</p> <p>4/24</p>
--	--	---	--	-------------------------------	-------------------------------------

		<p>October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG.</p> <p>November 2023 – to be discussed at next cardiology governance</p> <p>December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review</p> <p>February 2024 update: ongoing</p> <p>Ratification of guidelines and SCFs</p> <p>JM/AK to update formulary to match all asthma 3 guidelines</p> <p>October 2023: update ongoing</p> <p>December 2023: ongoing</p> <p>February 2024: action complete</p> <p>Feedback from Integrated Medicines Optimisation Committee</p> <p>Sodium valproate prevent compliance</p> <p>December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms.</p> <p>Ratification of guidelines and SCFs – azithromycin</p> <p>AK to discuss guidance with Dr Yasso</p> <p>November update: Discussed with Dr Yasso who is happy with the internal NLAG document. To add links to Azithromycin monograph in netFormulary for NICE guidance and asthma guidance.</p> <p>December update: JM to check all relevant guidance linked</p> <p>February 2024 update: action complete</p> <p>Ratification of guidelines and SCFs – JIC medication leaflet</p> <p>AK to send to St Andrews Hospice GP team.</p> <p>November update – contacted clinical directors and they were happy with content. Given a contact for logos and awaiting response</p> <p>December 2023 – Now have all logos and contact. JM to tidy up and publish on website.</p> <p>February 2024 - ongoing</p> <p>Ratification of guidelines and SCFs</p> <p>To update documents on website (when rimegepant funding confirmed)</p> <p>December update: needs new TA adding and funding confirmed for this</p>	<p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM/AK</p> <p>JM/KMc</p> <p>AK/JM</p> <p>AK</p> <p>JM</p>	<p>1/24</p> <p>4/24</p> <p>1/24</p> <p>1/24</p> <p>3/24</p>
--	--	---	--	---	---

	<p>February 2024 update: funding confirmed and action complete</p> <p>Ratification of joint formulary – chapter 6 To update netFormulary and remove HERPC chapter December update: ongoing February update: ongoing</p> <p>RTDC updates To update netFormulary with TAs and MHRA DSU</p> <p>Other issues – safety needles JM to update formulary to include relevant information December 2023 – ongoing February 2024 – action complete</p> <p>Other issues – Rocket IPC devices RSc to discuss with LMC Interface Officer for feedback to HUTH via commissioners</p> <p>AOB SR raised issue with turnaround requested by Spire. RSc to discuss with LMC Interface Officer for feedback</p> <p>Traffic Light Status To update Humber APC formulary</p> <p>Traffic Light Status To update HERPC formulary where needed</p> <p>Traffic Light Status To update HERPC red list</p> <p>Work plans To add review of guidance priority to guideline group meeting</p> <p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published</p> <p>Ratification of guidelines and SCFs To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance</p> <p>Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded</p> <p>Ratification of guideline and SCFs To update formulary with tirzepetide when funding and guidance approved and product available</p> <p>Ratification of joint formulary – chapter 12 To update netFormulary</p>	<p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p>	<p>JM/LS/AK</p> <p>JM/AK</p> <p>JM</p> <p>RSc</p> <p>RSc</p> <p>JM/LS/AK</p> <p>JM/LS</p> <p>JM/LS</p> <p>LS</p> <p>LS</p> <p>JM</p> <p>JM</p> <p>JM/AK</p> <p>LS/JM/AK</p>	<p>4/24</p> <p>1/24</p> <p>1/24</p> <p>2/24</p> <p>2/24</p> <p>1/24</p> <p>1/24</p> <p>1/24</p> <p>3/24</p> <p>3/24</p> <p>3/24</p> <p>4/24</p> <p>2/24</p> <p>6/24</p>
--	---	---	---	---

		<p>RTDC updates To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920)</p> <p>AOB To check for updated version of guidance and update on APC website and links in joint formulary</p>	Ongoing	JM/AO	2/24
			Action complete	JM	2/24
2024.02.05	Traffic Light Status	<p>Jan 2024: HUTH D&T: Secukinumab for Hidentritis supportiva (NHSE)- Proposed as RED Tirzepatide (TA924) classification to match guidance- Proposed as AMBER 1 Semaglutide (TA910) for use in HUTH tier 4 bariatric service- Proposed as RED Misc: Anthelios- Proposed as GREEN</p>	Update formularies/red list	JM/LS/AK	
2024.02.06	Feedback from Integrated Medicines Optimisation Committee	<ul style="list-style-type: none"> Shared care protocols Valproate First line DOAC 	Noted		
2024.02.07	Work plans	<p>a) Joint formulary alignment b) Shared care frameworks c) Guidelines</p>	Ongoing for information only		
2024.02.08	Ratification of guidelines and SCFs	<p>a) IBD guidance – JM summarised updates to the HUTH IBD guidance. Guidance has been updated to include TA888, TA856, TA905 and TA925 and pathway to include TA925. Guidance has been shared with NLAG team and will be discussed further to merge pathways at next review. b) Prescribing Anticoagulants including recommendations for NVAf (Amber guidance) – HERPC guidance reviewed and updated to</p>	<p>a) Approved; to upload pathway b) Approved c) Approved; to upload to website d) Approved e) Deferred to next meeting f) Approved</p>	JM	3/24

		<p>reflect new commissioning guidance from NHS England for NVAF. Apixaban added for orthopaedic use including off label use in HUTH. Dosing information added for enoxaparin. Paper regarding ICB wide change for recommendations for stroke prophylaxis in NVAF approved.</p> <p>c) Migraine and cluster headache (Amber guidance) – updated guidance with pathway and guidance for use of rimegapant in line with TA916.</p> <p>d) Care Home use of Homely remedies and skin tears – guidance for Hull and East Riding of Yorkshire care homes. Similar guidance already in place in Northern Lincolnshire places</p> <p>e) Ranolazine MR Tablets (Amber guidance) - deferred</p> <p>f) Symptom management in palliative care – to be adopted as ICB wide guidance, evidence of wide consultation with staff within all 4 places. Approved.</p>			
2024.02.09	Ratification of joint formulary	<ul style="list-style-type: none"> • Nil this month 			
2024.02.10	RTDC updates	<ul style="list-style-type: none"> • November 2023 • December 2023 	Update formulary/red list	JM/LS/AK	3/24
2024.02.11	Minutes from subcommittees	<p>a) Joint formulary subcommittee (Nil)</p> <p>b) Guideline subcommittee (Sept 2023)</p>	Attached for info only		
2024.02.12	Additional minutes for information	<p>a) HUTH D&TC (Nov 2023)</p> <p>b) HFT DTG (Sep 23 + Nov 23)</p> <p>c) NLAG M&T (Nil)</p> <p>d) NYY APC (Oct 23)</p>	Attached for info only		
2024.02.13	Correspondence received	Chapter 5 and guidance- Malaria guidance to be added	Update formulary	JM	3/24
2024.02.14	HAPC Newsletter Oct-Dec 23	Circulated and any comments to be sent to JM			
2024.02.15	AOB	<ul style="list-style-type: none"> • RSc noted pressure on primary care to prescribe medication and communication to bolster primary care confidence in prescribing said medication 			
2024.02.16	Date of next meeting	6 th March 2024 13.00 – 15.00 Teams			